Published online Sep 15, 2024. doi: 10.4251/wjgo.v16.i9.3851
Revised: July 30, 2024
Accepted: August 15, 2024
Published online: September 15, 2024
Processing time: 119 Days and 11.4 Hours
Hepatocellular carcinoma (HCC) is the third leading cause of cancer death world
To investigate the survival prognosis and clinical efficacy of surgical resection in patients with HCC complicated with HIV infection.
The clinical data of 56 patients with HCC complicated with HIV admitted to the Third Affiliated Hospital of Nantong University from January 2013 to December 2023 were retrospectively analyzed. Among these, 27 patients underwent hepatectomy (operation group) and 29 patients received conservative treatment (nonoperation group). All patients signed informed consents in line with the provisions of medical ethics. The general data, clinicopathological features and prognoses for the patients in the two groups were analyzed and the risk factors related to the prognoses of the patients in the operation group were identified.
The median disease-free survival (DFS) and overall survival (OS) of HIV-HCC patients in the surgical group were 13 months and 17 months, respectively, and the median OS of patients in the nonsurgical group was 12 months. The OS of the surgical group was significantly longer than that of the control group (17 months vs 12 months, respectively; P < 0.05). The risk factors associated with DFS and OS in the surgical group were initial HIV diagnosis, postoperative microvascular invasion (MVI), a CD4+ T-cell count < 200/μL, Barcelona stage C-D, and men who have sex with men (MSM; P < 0.05).
Hepatectomy can effectively prolong the survival of patients with HIV-HCC but MVI identified during post
Core Tip: Human immunodeficiency virus (HIV) infection significantly influences treatment strategies for hepatocellular carcinoma (HCC). When developing treatment plans, health care workers must consider the complexity of the immune status of HIV-infected patients and the potential drug interactions resulting from antiretroviral therapy. For HIV-positive HCC patients, HIV infection itself may influence tumor biology and patient response to treatment, thus affecting the cure, recurrence, and long-term survival rates of the disease. Therefore, health care professionals treating HIV-HCC patients must collaborate across disciplines to thoroughly understand the patient's overall condition and develop a comprehensive, personalized treatment plan. To effectively control HIV infection, HCC should be treated and the quality of life of patients should be optimized.